Lion Biotechnologies (LBIO) Enters Extended Agreement with CRADA; New Principal Accounting Officer Named
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Lion Biotechnologies (NASDAQ: LBIO) disclosed the following on Wednesday night:
Item 1.01. Entry into a Material Definitive Agreement.
In August 2011, Lion Biotechnologies, Inc. (“we” or the “Company”) entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), for research and development related to an adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL) in the treatment of metastatic melanoma. On January 22, 2015, we amended the CRADA to include four additional indications (in addition to metastatic melanoma, the CRADA therefore also covered the development of TIL therapy for the treatment of patients with bladder, lung, breast, and HPV-associated cancers). The original CRADA had a five -year term expiring in August 2016.
On August 18, 2016, the NCI and the Company entered into Amendment # 2 to the CRADA. The principal changes effected by Amendment #2 included (i) extending the term of the CRADA by another five years to August 2021, and (ii) modifying the focus on the development of TIL as a stand-alone therapy or in combination with FDA-licensed products and commercially available reagents routinely used for adoptive cell therapy. The parties will continue the development of improved methods for the generation and selection of TIL with anti-tumor reactivity in metastatic melanoma, bladder, lung, breast, and HPV-associated cancers. Except for the changes contained in Amendment #2, all other terms of the original CRADA (as amended to include the four additional indications) remain in full force and effect.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 22, 2016, Franco Valle assumed the position of interim principal accounting officer of the Company. Mr. Valle joined the Company as its Controller in July, 2016. Mr. Valle’s current annual salary is $230,000. In connection with his employment with the Company, Mr. Valle was granted stock options to purchase an aggregate of 85,000 shares of the Company’s common stock at an exercise price of $9.10.
Before he joined the Company, from May 2012 through April 2016 Mr. Valle worked at Pharmacyclics, Inc. in various positions, including most recently as the senior director of accounting. Prior thereto, Mr. Valle was the SEC reporting manager of Callidus Software, Inc. from October 2011 to May 2012. From July 2005 to October 2011, Mr. Valle worked at PricewaterhouseCoopers LLP in the life science, biotech and venture capital group. Mr. Valle is a certified public accountant and a graduate of San Jose State University.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Caterpillar (CAT) Offers FY17 Guidance Update at Credit Suisse Conference
- FMSA Holdings Inc. (FMSA) Files Mixed, Common Stock Shelf
- Sears Holdings (SHLD) Director Mnuchin Resigns Amid Trump Nod
Create E-mail Alert Related CategoriesCorporate News, Management Changes
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!